After unveiling a major restructuring initiative earlier this month, Genentech is sending 93 jobs in California to the chopping block.
Fierce Biotech
Information Services
New York, New York 91,281 followers
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
About us
Fierce Biotech is the dominant B2B news brand for the industry. Our focus daily is on biotech and medtech companies. We cover the drug and device development universe as well as the financing, deals, IPOs and M&A that happen along the way and the people who move biotech and medtech forward. Our coverage also feeds longer-form content, podcasts and events. Our journalists track the news closely and have developed a network of contacts to bring you exclusives. Our coverage runs the gamut from good news to bad and flattering to unflattering to give readers and listeners an unvarnished view of what’s truly happening. Delivering news, revealing insights straight to your inboxes: https://fiercebiotech.questexinfo.com/loading.do?omedasite=LS_full. Our family of publications includes Fierce Biotech, Fierce Biotech PM Tracker, Fierce Medtech, Fierce Biotech Research, Fierce CRO, Fierce Life Sciences Weekly Digest and Fierce Cell & Gene Therapy. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Pharma news you can’t miss: https://www.linkedin.com/company/fierce-pharma For Healthcare news you can’t miss: https://www.linkedin.com/showcase/fierce-healthcare
- Website
-
https://www.fiercebiotech.com/
External link for Fierce Biotech
- Industry
- Information Services
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Founded
- 2001
Updates
-
Flagship Pioneering and Pfizer have added Quotient into their 10-program partnership, inking a deal to discover new targets for two programs in cardiovascular and renal diseases.
After obesity, Pfizer and Flagship pick 2 more targets for multibillion-dollar partnership
fiercebiotech.com
-
Join the global community of medtech innovators at The MedTech Conference in Toronto, October 15-17, 2024! Connect with industry leaders, explore cutting-edge innovations, and experience the brand-new Medtech Campus. This is your chance to network, collaborate, and stay ahead of the curve. 🔗 https://loom.ly/tkdocFs With over 400 subject matter experts leading 100+ dynamic sessions, our premier education program delivers unparalleled insights into the future of the industry. Combine that with ample networking opportunities, and it’s clear—this is an event you can’t afford to miss. Register today! 🔗 https://loom.ly/tkdocFs #mtc24 #medtechcon #medtechinmotion
-
Fierce Biotech reposted this
Editor-in-Chief | Healthcare & Life Sciences | Fierce Pharma | Fierce Biotech | Fierce Healthcare | Questex
The Fierce Pharma, Fierce Biotech and Fierce Healthcare teams are finalists for three Eddie & Ozzie Awards this year! The caliber of journalists on our team is truly impressive, and I’m always proud when their work is recognized. No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis by Gabrielle Masson. (Analysis > B2B category): https://lnkd.in/d4UAq8CN The Fierce 50 of 2023 by the entire editorial team. This was a true team effort and a major undertaking. I’m incredibly proud of the 50 inspiring profiles featured in this project. (Profile or Q&A > B2B category): https://lnkd.in/dVb5wWhE This year's edition will go live in early September. And another great piece by Gabrielle Masson! Women left out of VC club fight for their identity, pulling each other up one by one (Single Article > B2B > Healthcare/Medical/Nursing category): https://lnkd.in/dCQZznkP
-
-
Indivior is picking up a small molecule allosteric modulator designed to treat substance use disorder from Addex Therapeutics, providing the latter the chance to make up to $300 million in biobucks, plus royalties.
After J&J-partnered epilepsy drug flop, Addex gets good news: Indivior has picked up its addiction asset
fiercebiotech.com
-
Navigator Medicines has equipped itself with $100 million in series A funds as the young biotech charts a course for its newly acquired autoimmune drugs.
Navigator charts course for newly acquired autoimmune pipeline with $100M series A
fiercebiotech.com
-
🚀 Drive Innovation at the Fierce Biotech Summit in Boston! Join Fierce Biotech editors and industry experts at the Fierce Biotech Summit in Boston (Sept. 30 - Oct. 1) as they tackle today’s biggest challenges in biotech. Gain exclusive insights into the recovery of the biotech industry, connect with the Fierce 15 honorees and network with over 500 biotech executives. Act fast—spots are filling up quickly: https://bit.ly/3AyapOg #FierceBiotech #FierceBiotechSummit #BiotechInnovation #StrategicPartnerships
-
-
Just days after gene editor Tome Biosciences announced undisclosed operational cuts, a clearer picture is coming into focus as 131 employees are being laid off.
Preclinical gene editor Tome is laying off 131 staffers, virtually its entire workforce
fiercebiotech.com
-
VA medical centers are at the forefront of healthcare innovation. Researchers and executives can leverage groundbreaking VA inventions through technology transfer, saving time and money while developing new products and services for the healthcare market. 🔗 https://bit.ly/3TnyqOX TechLink, the VA’s official technology transfer partner, plays a crucial role in helping companies license impactful technologies that benefit both patients and providers. Discover how Xenex collaborated with the VA to create TrackMate—a revolutionary disinfection tracking tool for portable medical equipment designed to minimize infection spread. 🔗 https://bit.ly/3TnyqOX #Sponsored
-
-
After raising $213 million in 2023—one of the year’s largest private biotech rounds—gene editor Tome is making cuts.
After $213M round, gene editing biotech Tome shrinks operations as investor sentiment worsens
fiercebiotech.com